TCG Crossover Management Beat the S&P 500 by 56 Points a Year: Its Q2 2026 13F Holdings
TCG Crossover Management's TCG Crossover Management, LLC Q2 2026 13F: top holdings, new buys, sales and returns vs the S&P 500, from the SEC filing of Aug 14.
TCG Crossover Management, LLC filed its Q2 2026 13F with the SEC on August 14, 2026, listing 54 positions worth $4.2B. Here is what changed from Q1 2026, the largest holdings, and how a portfolio copying them has done. The full holdings are on TCG Crossover Management's portfolio page.
TCG Crossover Management's top 10 holdings
| # | Stock | % of portfolio | Value | vs Q1 2026 |
|---|---|---|---|---|
| 1 | ABVX Abivax SA | 19.2% | $800.6M | -7.3% shares |
| 2 | TNGX Tango Therapeutics Inc | 6.8% | $283.9M | -13.8% shares |
| 3 | CGON Cg Oncology Inc | 6.3% | $260.8M | +0.0% shares |
| 4 | COGT Cogent Biosciences Inc | 4.5% | $187.9M | -1.9% shares |
| 5 | IMVT Immunovant Inc | 4.1% | $171.8M | +0.0% shares |
| 6 | SYRE Spyre Therapeutics | 4.1% | $168.7M | +0.0% shares |
| 7 | DNTH Dianthus Therapeutics Inc | 3.9% | $163.4M | +0.0% shares |
| 8 | MIRM Mirum Pharmaceuticals Inc | 3.0% | $124.3M | +0.0% shares |
| 9 | ZLAB Zai Lab Ltd | 2.8% | $116.6M | New |
| 10 | AMLX Amylyx Pharmaceuticals Inc | 2.7% | $112.1M | +0.0% shares |
New positions in Q2 2026
- ZLAB Zai Lab Ltd: 2.8% of the portfolio, $116.6M
- AURA Aura Biosciences Inc: 1.6% of the portfolio, $67.7M
- TRAX First Tracks Biotherapeutics: 1.4% of the portfolio, $58.3M
- EDIT Editas Medicine Inc: 0.9% of the portfolio, $36.0M
- PHVS Pharvaris N V: 0.8% of the portfolio, $34.9M
- Inflarx NV Inflarx NV: 0.8% of the portfolio, $32.5M
- ALT Altimmune Inc: 0.7% of the portfolio, $30.4M
- AKTS Aktis Oncology Inc: 0.5% of the portfolio, $22.5M
- FBRX Forte Biosciences Inc: 0.5% of the portfolio, $19.6M
- RACC Research Alliance Corp III: 0.1% of the portfolio, $5.3M
Biggest additions
- AVTX Avalo Therapeutics Inc: +308.6% shares, now 1.3%
- MNPR Monopar Therapeutics Inc: +53.9% shares, now 0.5%
What they sold
- CNTA Centessa Pharmaceuticals PLC: out of the top 50 (was 4.9%)
- FULC Fulcrum Therapeutics Inc: out of the top 50 (was 1.2%)
- LQDA Liquidia Corporation: out of the top 50 (was 0.4%)
- URGN Urogen Pharma Ltd: out of the top 50 (was 0.2%)
- CNTX Context Therapeutics Inc: out of the top 50 (was 0.2%)
- GPCR Structure Therapeutics Inc: out of the top 50 (was 0.2%)
- LONA Leonabio Inc: out of the top 50 (was 0.1%)
- UPB Upstream Bio Inc: out of the top 50 (was 0.0%)
- ABVX Abivax SA: -7.3% shares
- TNGX Tango Therapeutics Inc: -13.8% shares
- RVMD Revolution Medicines Inc: -40.9% shares
- LBRX LB Pharmaceuticals, Inc.: -21.3% shares
- BHVN Biohaven Ltd: -61.6% shares
- ALXO Alx Oncology Hldgs Inc: -56.5% shares
Has TCG Crossover Management beaten the market?
A portfolio holding TCG Crossover Management's 20 largest 13F positions, bought once each filing was public and rebuilt every quarter, returned +136.6% a year over 1 year (S&P 500 +20.1%), +69.9% a year over 3 years (S&P 500 +21.8%) and +86.4% a year over 5 years (S&P 500 +17.4%). 13Fs show only long US stock positions with up to a 45-day delay, so this measures the stock picks a cloner could have copied, not the fund's own returns.
Questions and answers
What stocks does TCG Crossover Management own?
As of the Q2 2026 13F, TCG Crossover Management's largest holdings are Abivax SA (ABVX) at 19.2%, Tango Therapeutics Inc (TNGX) at 6.8%, Cg Oncology Inc (CGON) at 6.3%, Cogent Biosciences Inc (COGT) at 4.5% and Immunovant Inc (IMVT) at 4.1%.
What did TCG Crossover Management buy in Q2 2026?
New positions in Zai Lab Ltd (ZLAB), Aura Biosciences Inc (AURA), First Tracks Biotherapeutics (TRAX), Editas Medicine Inc (EDIT) and Pharvaris N V (PHVS), and added to Avalo Therapeutics Inc (AVTX) and Monopar Therapeutics Inc (MNPR).
When is TCG Crossover Management's next 13F filing?
13F filings are due 45 days after each quarter ends; TCG Crossover Management, LLC's next one is due by November 14, 2026.
Sources: SEC Form 13F-HR filed 2026-08-14. Written from the data on this site on Oct 30, 2026; every figure links to the page it comes from. Not investment advice.